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Background: To study the pathogenesis of diabetic cardiomyopathy, reliable animal models of type 2 diabetes are
required. Physiologically relevant rodent models are needed, which not only replicate the human pathology but
also mimic the disease process. Here we characterised cardiac metabolic abnormalities, and investigated the
optimal experimental approach for inducing disease, in a new model of type 2 diabetes.
Methods and results: Male Wistar rats were fed a high-fat diet for three weeks, with a single intraperitoneal
injection of low dose streptozotocin (STZ) after fourteen days at 15, 20, 25 or 30 mg/kg body weight. Compared
with chow-fed or high-fat diet fed control rats, a high-fat diet in combination with doses of 15–25 mg/kg STZ did
not change insulin concentrations and rats maintained body weight. In contrast, 30 mg/kg STZ induced
hypoinsulinaemia, hyperketonaemia and weight loss. There was a dose-dependent increase in blood glucose and
plasma lipids with increasing concentrations of STZ. Cardiac and hepatic triglycerides were increased by all doses of
STZ, in contrast, cardiac glycogen concentrations increased in a dose-dependent manner with increasing STZ
concentrations. Cardiac glucose transporter 4 protein levels were decreased, whereas fatty acid metabolism-
regulated proteins, including uncoupling protein 3 and pyruvate dehydrogenase (PDH) kinase 4, were increased
with increasing doses of STZ. Cardiac PDH activity displayed a dose-dependent relationship between enzyme
activity and STZ concentration. Cardiac insulin-stimulated glycolytic rates were decreased by 17% in 15 mg/kg STZ
high-fat fed diabetic rats compared with control rats, with no effect on cardiac contractile function.
Conclusions: High-fat feeding in combination with a low dose of STZ induced cardiac metabolic changes that
mirror the decrease in glucose metabolism and increase in fat metabolism in diabetic patients. While low doses of
15–25 mg/kg STZ induced a type 2 diabetic phenotype, higher doses more closely recapitulated type 1 diabetes,
demonstrating that the severity of diabetes can be modified according to the requirements of the study.Introduction
The incidence of type 2 diabetes continues to increase,
despite the best current therapies and educational pro-
grams available. Cardiovascular disease is the leading
cause of mortality in type 2 diabetic patients in the
United Kingdom [1]. Metabolic changes in the heart
have been implicated in the increased incidence of
myocardial infarction [2], with diabetic patients having
decreased cardiac glucose metabolism and increased* Correspondence: Lisa.heather@dpag.ox.ac.uk
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reproduction in any medium, provided the orcardiac fatty acid metabolism [3-6]. Therefore, a greater
understanding of how type 2 diabetes affects the heart,
the role of abnormal cardiac metabolism and how novel
interventions could circumvent this are needed.
Animal models of type 2 diabetes are currently the
first line for investigating disease mechanisms and
pharmacological therapies. For relevance to humans,
animal models must replicate the phenotype seen in pa-
tients as closely as possible, but it is also desirable that
they mimic the developmental process of the disease.
From a practical perspective, models that are easy to
generate, cheap and develop in a timely manner will be
favoured over expensive and time-consuming models.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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models of type 2 diabetes have been associated with a
number of drawbacks (comprehensively reviewed by
Bugger and Abel [7]). For example, the db/db mouse,
ob/ob mouse and Zucker fatty rat have been extensively
studied in the literature [8-11], and are generated by
genetic abnormalities in the leptin signalling pathway,
whereas, in patients, type 2 diabetes usually results as a
consequence of multiple gene polymorphisms in com-
bination with environmental factors. Similarly, the Goto-
Kakizaki GK rat is insulin resistant but remains lean
[12,13], making comparisons to the human condition
and its association with obesity difficult. Another draw-
back of spontaneously diabetic and transgenic animals is
the expensive cost of purchase [14]. In relation to car-
diac research, one of the limitations of current rat
models is the extended periods taken to develop cardiac
phenotypes, despite the presence of abnormal circulating
metabolites from an early age. For example, Zucker dia-
betic rats only show cardiac metabolic dysfunction after
12 weeks of age [15], and Zucker fatty rats only after
12 months [16]. Similarly, high-fat diet alone isn’t effect-
ive at modifying cardiac and systemic metabolism unless
fed over an extended period [17].
A relatively new rat model was proposed first by Reed
et al. [18], with modifications by Srinivasan et al. [19],
which aimed to induce type 2 diabetes by using high-fat
feeding to induce peripheral insulin resistance, followed
by a low dose of the pancreatic β-cell toxin, streptozotocin
(STZ). STZ is traditionally used at high doses to induce
type 1 diabetes, as it results in impaired insulin secretion
from the β-cell [20,21]. Reed et al. proposed that if a low
dose of STZ was used after high-fat feeding, the function
of the β-cell mass would be modestly impaired without
completely compromising insulin secretion, resulting in a
moderate impairment in glucose tolerance [18,19]. This
would mimic the human disease process resulting in a
metabolic phenotype similar to that in late stage type 2
diabetic patients. This model has become increasingly
popular in recent years, both for investigating the mecha-
nisms involved in type 2 diabetes and for testing potential
therapies [22-26]. However, the degree of diabetes in-
duced, the amount of STZ used, background strain and
starting body weight vary considerably between these
studies. As examples, Reed et al. administered 50 mg/kg
STZ via an intravenous route following anaesthesia,
Srinivasan et al. used 35 mg/kg STZ administered intra-
peritoneally but using relatively juvenile rats, whereas
Zhang et al. fed rats on a high-fat diet for 2 months prior
to STZ [18,19,27]. Therefore, a better understanding of
the cardiac phenotype of this model, the metabolic
changes associated with this method of inducing diabetes
and determining the optimal protocol would be desirable
prior to use in large scale studies.Therefore, we set out to determine whether this high-fat
feeding/low dose STZ model of type 2 diabetes modified
cardiac metabolism in a similar manner to the human dis-
ease. In addition, we aimed to determine the optimal experi-
mental approach to induce the disease by testing the cardiac
effects of a variety of STZ doses in mature adult Wistar rats.
Rats were fed a high-fat diet for three weeks, with a single
intraperitoneal injection of STZ of either 15, 20, 25 or
30 mg/kg body weight after two weeks. Our results showed
that inducing type 2 diabetes, using a combination of high-
fat feeding with a low dose of STZ, mimics the human
condition. We also demonstrate that while low doses of
STZ induced type 2 diabetes and cardiac metabolic changes,
a dose of 30 mg/kg induced overt and severe systemic alter-
ations that more closely resembled type 1 diabetes.
Methods
Rat model of type 2 diabetes
Male Wistar rats (n = 55, 260 ± 7 g) were obtained from a
commercial breeder (Harlan, UK). All procedures were in
accordance with Home Office (UK) guidelines under The
Animals (Scientific Procedures) Act, 1986 and with insti-
tutional guidelines. Control rats were fed for three weeks
on a standard chow diet (Harlan Laboratories), with an
Atwater Fuel Energy of 3.0 kcal/g, comprising 66% calo-
ries from carbohydrate, 22% from protein and 12% from
fat (Additional file 1: Table S1). To induce diabetes, rats
were fed a high-fat diet (Special Diet Services) for three
weeks, with an Atwater Fuel Energy of 5.3 kcal/g, com-
prising 60% calories from fat, 35% from protein and 5%
from carbohydrate, according to a modification of the pro-
tocols of Reed et al. and Srinivasan et al. [18,19]. On day
13, rats were fasted overnight and given a single intraperi-
toneal injection of streptozotocin (STZ in citrate buffer,
pH 4) the following morning, and the high-fat diet feeding
was continued for a further week (or chow diet for con-
trols). Different doses of STZ (0, 15, 20, 25 and 30 mg/kg
bodyweight w/w) in combination with high-fat diet, were
investigated to determine the optimal dose to induce a
type 2 diabetic phenotype with modified cardiac metabol-
ism. We started our study with a dose of 30 mg/kg, to
closely replicate that used by others [19], then included
additional groups on lower doses of STZ until hypergly-
caemia was no longer induced, mortality was not observed
with any dose of STZ. After three weeks on their desig-
nated diet, rats in the fed state were terminally
anaesthetised with sodium pentobarbital, hearts and livers
were rapidly excised, freeze clamped and stored at −80°C
for subsequent analysis. Following excision of the heart,
blood was collected from the chest cavity, plasma sepa-
rated and analysed for metabolites using a Pentra analyser
(ABX, UK) and an insulin ELISA (Mercodia, Sweden).
Both left and right epididymal fat pads were excised,
trimmed and weighed, for assessment of adiposity.
Mansor et al. Cardiovascular Diabetology 2013, 12:136 Page 3 of 10
http://www.cardiab.com/content/12/1/136Tissue analysis
Cardiac and hepatic glycogen content were determined
by the breakdown of glycogen to glucose units, using
amyloglucosidase. Triglyceride content was measured in
cardiac and hepatic tissue, following Folch extraction,
using a kit from Randox, UK. The active fraction of
pyruvate dehydrogenase was assayed in cardiac homoge-
nates according to the protocol of Seymour et al. [28].
Medium chain acyl-coenzyme A dehydrogenase activity
in cardiac homogenates was measured by following the
decrease in ferricinium ion absorbance, as described by
Lehman et al. [29]. Citrate synthase activity was mea-
sured in cardiac homogenates according to the method
of Srere [30].
Western blotting
Cardiac lysates were prepared from frozen tissue and
equal concentrations of protein were loaded and sepa-
rated on 12.5% SDS-PAGE gels, and transferred onto
immobilon-p membranes (Millipore, UK) [31]. FAT/
CD36 was detected with an antibody kindly donated by
Dr Narendra Tandon (Otsuka Maryland Medicinal La-
boratories, USA) [32]. Prof. Geoff Holman (University of
Bath, UK) kindly donated the GLUT4 antibody [33,34].
PDK4 was detected using an antibody kindly donated by
Prof. Mary Sugden (Queen Mary’s, University of London,
UK) [35]. Antibodies against GLUT1 and UCP3 were pur-
chased from Abcam, UK, and against monocarboxylate
transporter (MCT) 1 from Santa Cruz. Even protein load-
ing and transfer were confirmed by Ponceau staining.
Isolated heart perfusion
A second group of rats were treated with the lowest
dose of STZ (15 mg/kg) in combination with high-fat
diet, to investigate the effect on cardiac glycolytic flux in
the isolated perfused heart. Hearts were isolated into
ice-cold Krebs-Henseleit (KH) buffer, cannulated via the
aorta and perfused in Langendorff mode at a constant
perfusion pressure of 100 mmHg at 37°C [31]. HeartsTable 1 Physical parameters from control and diabetic rats, in
dose STZ
Control
Total body weight gain (g) 69 ± 3
Body weight change during two weeks of diet modification (g) 46 ± 1
Body weight change in final week following STZ or control (g) 23 ± 4
Epidydimal fat pad weight (g) 4.8 ± 0.4
Epidydimal fat pad to body weight ratio (%) 1.5 ± 0.1
Heart weight (g) 1.2 ± 0.1
Heart to body weight ratio (× 103) 3.6 ± 0.2
* p < 0.05 vs. control, † p < 0.05 vs. all other doses of STZ, # p < 0.05 vs. 15 mg/kg Swere perfused with 200 ml recirculating KH buffer
(118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.3 mM
CaCl2, 0.5 mM EDTA, 25 mM NaHCO3, 1.2 mM
KH2PO4, pH 7.4) containing 11 mM glucose and 3 U/L
insulin, gassed with 95% O2 and 5% CO2.
To measure functional changes during the perfusion
protocol, a fluid filled, PVC balloon was inserted into
the left ventricle, inflated to achieve an end-diastolic
pressure of 4 mmHg, and attached via a polyethylene
tube to a bridge amplifier and PowerLab data acquisition
system (ADInstruments, Oxfordshire, UK). Left ven-
tricular developed pressure was determined as systolic
pressure minus end-diastolic pressure. Rate pressure
product was calculated as the product of developed
pressure and heart rate. To measure glycolytic rates, the
KH buffer was supplemented with 0.2 μCi.ml-1 [5-3H]-
glucose and timed aliquots of perfusate were collected
during the perfusion protocol. Glycolytic rates were de-
termined from the conversion of 3H-glucose to 3H2O in
the aliquots.
Statistics
Results are presented as means ± SEM, and were consid-
ered significant at p < 0.05 (SPSS Statistics 18). Differ-
ences between all six groups (control, 0, 15, 20, 25 and
30 mg/kg STZ) were investigated using a one-way
ANOVA with Tukey post-hoc correction for multiple
comparisons. To investigate the STZ dose-dependent ef-
fects, a two tailed regression analysis was performed be-
tween the five doses of STZ.
Results
Physical parameters
Control rats gained 69 ± 3 g in body weight over the
three week protocol, averaging 23 ± 4 g per week (Table 1
and Additional file 2: Figure S1). Following the injection
of STZ at day 14, the lower doses of STZ (0, 15, 20 and
25 mg/kg) did not alter total body weight gain or body
weight gain in the final week compared with the controlduced using high-fat feeding in combination with low
Diabetes model
(High-fat feeding with low dose STZ)
0 mg/kg 15 mg/kg 20 mg/kg 25 mg/kg 30 mg/kg
82 ± 7 88 ± 15 93 ± 5 77 ± 9 50 ± 9 #
49 ± 7 56 ± 12 60 ± 2 55 ± 8 55 ± 7
33 ± 5 32 ± 2 33 ± 3 22 ± 4 −5 ± 4 *†
7.0 ± 0.7 5.7 ± 0.4 7.6 ± 0.7 9.8 ± 0.6 *# 8.3 ± 0.7 *
2.0 ± 0.2 1.8 ± 0.1 2.4 ± 0.2 * 2.5 ± 0.1 * 2.3 ± 0.2 *
1.2 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 1.0 ± 0.1 1.1 ± 0.1
3.5 ± 0.1 3.4 ± 0.2 3.4 ± 0.2 3.2 ± 0.2 3.1 ± 0.1
TZ. n = 11 for control groups, n = 4 for diabetic groups.
Table 2 Plasma metabolites from control and diabetic rats in the fed state, induced using high-fat feeding in
combination with low dose STZ
Diabetes model
(High-fat feeding with low dose STZ)
Control 0 mg/kg 15 mg/kg 20 mg/kg 25 mg/kg 30 mg/kg
Glucose (mmol/l) 12.7 ± 0.3 14.6 ± 1.8 14.7 ± 0.6 17.2 ± 1.2 * 16.9 ± 1.5 * 25.1 ± 1.1 *†
Insulin (ug/l) 3.03 ± 0.51 2.68 ± 0.57 2.00 ± 0.31 1.59 ± 0.36 1.93 ± 0.26 1.04 ± 0.22 *
NEFA (mmol/l) 0.28 ± 0.06 0.29 ± 0.05 0.29 ± 0.02 0.29 ± 0.01 0.14 ± 0.04 0.59 ± 0.07 *#
Triglycerides (mmol/l) 1.79 ± 0.20 1.13 ± 0.22 0.87 ± 0.06 1.41 ± 0.15 1.79 ± 0.35 7.25 ± 1.33 *†
β-OHB (mmol/l) 0.26 ± 0.04 0.33 ± 0.04 0.45 ± 0.07 0.77 ± 0.06 0.98 ± 0.21 5.39 ± 0.59 *†
Cholesterol (mmol/l) 2.46 ± 0.13 2.07 ± 0.21 1.68 ± 0.15 2.11 ± 0.27 3.87 ± 0.58 *$ 3.02 ± 0.44 €
* p < 0.05 vs. control, † p < 0.05 vs. all other doses of STZ, # p < 0.05 vs. 15 and 25 mg/kg, $ p < 0.05 vs. 0, 15 and 20 mg/kg, € p < 0.05 vs. 15 mg/kg. NEFA non-
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Figure 1 Hepatic triglyceride and glycogen concentrations in
control and diabetic rats following high-fat feeding in
combination with low dose STZ. * p < 0.05 vs. control, # p < 0.05
vs. high-fat only, n = 10 for control group, n = 4 for diabetic groups.
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weight loss in the final week despite the continuation of
the high-fat diet, compared with the control group and
other lower doses of STZ. There was a significant correl-
ation between body weight gain in the final week and
STZ doses (r2 = 0.33, p < 0.05). Epididymal fat pad
weight, an indicator of total body adiposity, and fat pad
to body weight ratio were significantly increased with
higher doses of STZ compared with controls. Heart
weight and heart weight to body weight ratio were not
significantly different between any groups, demonstrat-
ing no significant cardiac hypertrophy.
Plasma metabolites in the fed state
Blood glucose concentrations were not increased by
high-fat diet alone or in combination with 15 mg/kg
STZ, compared with control chow fed rats (Table 2). In
contrast, blood glucose levels were increased by 20, 25
and 30 mg/kg STZ in combination with a high-fat diet,
with the 30 mg/kg STZ dose increasing blood glucose
significantly higher than all other groups. Plasma insulin
concentrations were not significantly different to control
animals at lower doses of STZ, but were significantly de-
creased by 30 mg/kg STZ. Non-esterified fatty acids
(NEFA), triglyceride, and β-hydroxybutyrate (β-OHB) con-
centrations were increased only with the highest dose of
STZ (30 mg/kg), compared with controls and the other
doses of STZ investigated. Cholesterol concentrations
were elevated by administration of 25 mg/kg STZ in
combination with high-fat feeding compared with con-
trols and lower doses of STZ. Regression analysis dem-
onstrated significant positive relationships between STZ
dose and plasma glucose (r2 = 0.37), triglycerides (r2 =
0.30), β-OHB (r2 = 0.41) and cholesterol (r2 = 0.20), and
significant negative relationships between STZ dose and
plasma insulin (r2 = 0.25) (p < 0.05 for all). Thus, while
lower doses of 20–25 mg/kg STZ were sufficient to ele-
vate blood glucose levels without impairing insulin secre-
tion, the higher dose of STZ caused severe diabetes, asshown by increased glucose, β-OHB, triglycerides and de-
creased insulin concentrations.
Hepatic intracellular substrate stores
Hepatic triglyceride and glycogen stores were measured
as an indicator of changes in liver metabolism. Three
weeks of high-fat diet alone did not change hepatic tri-
glyceride or glycogen concentrations compared with
controls (Figure 1). Combining high-fat diet with all
doses of STZ tested increased hepatic triglyceride concen-
trations, compared with control rat livers. In contrast,
hepatic glycogen concentrations were decreased following
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ation with STZ at doses of 15, 20 and 30 mg/kg STZ. Both
measurements correlated with STZ dose (triglycerides r2
= 0.39, glycogen r2 = 0.23, p < 0.05).
Cardiac intracellular substrate stores
One of the main aims of this study was to characterise
the cardiac metabolic phenotype of this new model of
type 2 diabetes. Cardiac triglyceride concentrations were
increased by all doses of STZ tested, compared with
control rats, but not by high-fat diet alone, displaying a
significant positive correlation with STZ dose (Figure 2).
Cardiac glycogen concentrations were decreased by
high-fat diet and lower doses of STZ (15 and 20 mg/kg),
but showed a dose-dependent increase with STZ con-
centration. The highest dose of STZ tested (30 mg/kg)
did not change cardiac glycogen concentrations com-
pared with controls, and was significantly higher than
lower doses of STZ (15 and 20 mg/kg).
Cardiac enzyme assays
Cardiac pyruvate dehydrogenase (PDH) activity, a heavily
regulated enzyme of mitochondrial glucose metabolism,
was significantly decreased in diabetic hearts at a dose of
30 mg/kg STZ, compared with controls (Figure 3). There
was a significant negative correlation between PDH activ-
ity and STZ dose. In contrast, medium chain acyl-








































































Figure 2 Cardiac triglyceride and glycogen concentrations in control
low dose STZ. * p < 0.05 vs. control, # p < 0.05 vs. high-fat only, † p < 0.05
diabetic groups.involved in fatty acid β-oxidation, was significantly in-
creased in 30 mg/kg STZ diabetic rats, compared with
controls. These changes in PDH and MCAD activity were
independent of a change in the Krebs cycle enzyme citrate
synthase, used as a marker of overall mitochondrial
content.
Cardiac metabolic proteins
As the changes in metabolic enzymes displayed dose-
dependent relationships between STZ dose and activ-
ities, we, therefore, investigated which doses of STZ in-
duced changes in metabolic protein expression. Proteins
involved in cardiac glucose metabolism were investigated
in our model of type 2 diabetes, to determine if this
pathway was downregulated in diabetic hearts (Figure 4).
Protein levels of the PDH inhibitor pyruvate dehydro-
genase kinase 4 (PDK4), were increased by all doses of
STZ compared with controls. In contrast, the insulin-
responsive glucose transporter, GLUT4, protein levels
decreased with all doses of STZ, compared with control
hearts. Both PDK4 and GLUT4 displayed dose-
dependent relationships with STZ concentrations (r2 =
0.53 and r2 = 0.22, respectively, p < 0.05). GLUT1 protein
levels showed no significant differences between groups.
Markers of cardiac fatty acid metabolism were also
assessed, to determine if this pathway was upregulated
in our diabetic hearts (Figure 5). Uncoupling protein 3























High-fat diet with STZ (mg/kg)
p < 0.05, r2 = 0.25


























p < 0.01, r2 = 0.33
#
and diabetic rats following high-fat feeding in combination with



































































High-fat diet with STZ (mg/kg)
15 3025200








































































High-fat diet with STZ (mg/kg)
p < 0.000, r2 = 0.51
#
Figure 3 Cardiac pyruvate dehydrogenase, medium chain acyl-coenzyme A dehydrogenase (MCAD) and citrate synthase activities in
control and diabetic rats following high-fat feeding in combination with low dose STZ. * p < 0.05 vs. control, # p < 0.05 vs. high-fat only,
† p < 0.05 vs. 15 and 20 mg/kg STZ, n = 4–5 per group.
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ing in a dose-dependent manner with STZ concentration
(r2 = 0.34, p < 0.05). FAT/CD36, a fatty acid transporter,
was not significantly different between groups when
assessed by one way ANOVA. MCT1, responsible for ke-
tone body and monocarboxylic acid uptake, was mea-
sured, to determine if changes in this transporter
mirrored changes in plasma ketone bodies. There were
no significant differences between groups in cardiac
MCT1 protein levels, although there was a general trend
for lower levels in diabetic hearts compared with control
hearts.
Cardiac glycolytic rates from 15 mg/kg STZ high-fat fed
diabetic rats
All doses of STZ investigated showed a downregulation
of glucose metabolism proteins, therefore, we questioned
whether this was sufficient to affect flux through the
glycolytic pathway in the perfused, contracting heart.
Given that a number of metabolic changes in these
hearts displayed a dose-dependent relationship, we
rationalised that if we saw a change in glycolysis with
the lowest dose (15 mg/kg STZ), then this would likely
indicate that overall the model was sufficient to inhibit
cardiac glucose metabolic flux (Figure 6).
Hearts from 15 mg/kg STZ high-fat fed diabetic rats
did not show any defects in contractile function. Heartrates (284 ± 13 and 264 ± 5 bpm in control and diabetic
hearts, respectively), developed pressures (165 ± 10 and
182 ± 10 mmHg in control and diabetic hearts, respect-
ively), and rate pressure products (47 ± 4 and 48 ± 3 ×
103 mmHg/min in control and diabetic hearts, respect-
ively) were not significantly different between control
and 15 mg/kg STZ diabetic hearts. In contrast, glycolytic
rates in the presence of insulin were significantly de-
creased by 17% in 15 mg/kg type 2 diabetic rat hearts
compared with control hearts. Thus, even at the lowest
dose of STZ, glycolytic rates were suppressed in the
hearts of these type 2 diabetic rats.
Discussion
This study has demonstrated that high-fat feeding in
combination with a low dose of STZ is sufficient to in-
duce the cardiac metabolic phenotype present in type 2
diabetes. In general, this model displayed hypergly-
caemia, normoinsulinaemia and hepatic lipid deposition.
Diabetic hearts had decreased proteins involved in glu-
cose metabolism with a concomitant increase in proteins
involved in fat metabolism. Many metabolic parameters
displayed a dose-dependent relationship with STZ, with
the highest dose of STZ inducing a metabolic profile
that more closely resembled type 1 diabetes. Therefore,
this model of type 2 diabetes would appear to mirror the




































Figure 6 Glycolytic rates in isolated perfused hearts from
control and 15 mg/kg STZ in combination with high-fat fed









































































































Diabetes model – high-fat diet with STZ (mg/kg)
Figure 5 Cardiac uncoupling protein 3 (UCP3), fatty acid
translocase (FAT/CD36) and monocarboxylate transporter 1
(MCT1) protein levels in control and diabetic rats following
high-fat feeding in combination with low dose STZ. * p < 0.05
vs. control, † p < 0.05 vs. all other doses of STZ, n = 6 for control











































































































Diabetes model – high-fat diet with STZ (mg/kg)
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Diabetes model – high-fat diet with STZ (mg/kg)
15 302520
Figure 4 Cardiac pyruvate dehydrogenase kinase 4 (PDK4),
glucose transporters (GLUT) 4 and 1 protein levels in control
and diabetic rats following high-fat feeding in combination
with low dose STZ. * p < 0.05 vs. control, † p < 0.05 vs. all other
doses of STZ, n = 6 for control group, n = 4 for diabetic groups.
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degree of diabetes induced.
The highest dose of STZ tested (30 mg/kg) induced
systemic changes that more closely resembled the type 1
diabetic phenotype. Only this high dose of STZ induced
weight loss, and produced a plasma metabolite profile
that included hyperketonaemia, hyperlipidaemia, and
hypoinsulinaemia. This is in agreement with other stud-
ies that have used high doses of STZ in isolation or in
combination with high-fat feeding [19,36-39], with these
high doses also causing abnormalities in liver morph-
ology and function [25]. In contrast, the lower doses of
STZ investigated in the present study avoided these ex-
treme phenotypes, instead presenting with hypergly-
caemia in the absence of ketosis, normoinsulinaemia and
with maintenance of body weight. Increased adiposity
relative to body weight was observed with doses of 20,
25 and 30 mg/kg STZ, and wasn’t present with high-fat
diet only, demonstrating a combined effect of the dietary
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adiposity and elevated cholesterol induced by 25 mg/kg
STZ are features present in other models of type 2 dia-
betes [40-42], suggesting that, from a systemic point of
view, the middle range dose of STZ tested was the most
desirable for future work.
In patients with type 2 diabetes, non-invasive imaging
studies have demonstrated a metabolic shift in cardiac
substrate metabolism [3-6], with glucose metabolism
suppressed and fatty acids metabolism elevated, charac-
teristic of the Randle cycle [43]. This metabolic shift has
been demonstrated in a number of animal models of
diabetic cardiomyopathy [44,45], and has been impli-
cated in the increased incidence of, and decreased recov-
ery following, myocardial infarction [2]. In our diabetic
hearts, we found markers of fatty acid oxidation, such as
UCP3, were upregulated. UCP3, MCAD and PDK4 are
peroxisome proliferator-activated receptor α (PPARα)
targets, a transcription factor that is activated by fatty
acid ligands to upregulate fat metabolism, and is in-
creased in diabetes [46]. The activation of PPARα in dia-
betes is due to both the increased intake of dietary fatty
acids, in addition to increased adipose lipolysis associ-
ated with adipose insulin resistance [47]. In contrast to
fatty acid metabolism, proteins involved in cardiac glu-
cose metabolism, such as GLUT4, were downregulated
in our diabetic hearts. Certainly, the large increase in
PDK4 with 30 mg/kg STZ, would account for the de-
crease in PDH activity in these hearts via inhibitory
phosphorylation of this complex. Thus, the changes in
protein and enzyme activity in our diabetic hearts would
fully support the shift away from glucose metabolism to-
wards fat metabolism, reported in other models and in
patient studies [48]. Future studies to measure the ef-
fects on fatty acid and oxidative metabolism in this
model will confirm the link between the changes in
mitochondrial proteins and flux through these pathways.
Perfused heart studies allow the simultaneous meas-
urement of metabolic flux and contractile function in
the isolated organ. Even at the lowest dose of STZ,
glycolytic rates were decreased, confirming that our
changes in proteins were sufficient to impact on overall
flux through the pathway, in agreement with studies on
db/db and ob/ob mice [44,45,49,50]. The decrease in gly-
colysis was independent of impaired cardiac systolic
function or loss of mitochondria, suggesting that the
glycolytic changes were not secondary to adverse cardiac
remodelling and mitophagy. In a clever study by Marsh
et al., the interaction between diet and diabetes on car-
diovascular function was investigated, using a similar
model to our current study [51]. They demonstrated that
a combination of high-fat feeding and low dose STZ in-
creased diastolic wall stress and arterial stiffness, as oc-
curs in patients with type 2 diabetes, but that modifyingonly diet or using only STZ did not produce this effect,
despite increased blood glucose and abnormal insulin
tolerance tests, respectively [51]. Thus, inducing type 2
diabetes using high-fat feeding and low dose STZ, not
only mimics the cardiac metabolic phenotype but also
replicates the diastolic dysfunction and vascular compli-
cations associated with the human disease.
Overall, these data support the use of the high-fat
diet/low dose STZ approach in the development of a
type 2 diabetic model for future cardiac studies. The ad-
vantages of this model are that the disease is induced
over a relatively short time and without high costs. In
addition, the dose of STZ can be manipulated to match
the degree of diabetes required for the study. In a study
by Watts et al., this model of high-fat diet and low dose
STZ was used and directly compared to the ZDF rat,
with both models demonstrating the same hepatic and
adipose effects, but the errors associated with the ZDF
animals were much greater than with the high-fat/STZ
model, suggesting that the reproducibility may be im-
proved by using this new model [22]. Similarly, in a
study by Islam and Choi, the high-fat diet in combin-
ation with low dose STZ model was identified as a better
model of type 2 diabetes than an alternative chemically-
induced model that utilised an injection of nicotinamide
prior to administration of STZ [37]. We found it was es-
sential to fast the rats prior to STZ injection, as prelim-
inary experiments demonstrated a much lower success
rate for inducing diabetes if injections were carried out
in the fed state (data not shown). This is likely related to
the mode of action of STZ, a glucosamine-nitrosourea
antibiotic that competes with blood glucose for the pan-
creatic β-cell GLUT2 receptor [20].
Hepatic and cardiac triglyceride concentrations were
elevated by all doses of STZ tested but not by high-fat
diet alone, indicating that this was due to the combin-
ation of STZ and high-fat. Hepatic and cardiac glycogen
concentrations showed dose-dependent relationships
with STZ concentrations, but in opposite directions in
the two organs; decreasing in liver but increasing in
heart. Interestingly, hepatic glycogen was not affected by
high-fat diet alone, in contrast, cardiac glycogen was sig-
nificantly decreased just by the presence of high-fat diet,
demonstrating different regulation of glycogen depos-
ition in these two organs.
From our data, doses of 30 mg/kg STZ (and poten-
tially above) would be less desirable than lower doses for
modelling type 2 diabetes, due to the extreme systemic
phenotype induced. However, at no time did we see an
increase in fed insulin concentrations, which has been
observed in a number of other models. It has been sug-
gested that this is due to STZ causing a small degree of
β-cell damage, which is sufficient to limit the
upregulation of insulin secretion in response to the
Mansor et al. Cardiovascular Diabetology 2013, 12:136 Page 9 of 10
http://www.cardiab.com/content/12/1/136systemic insulin resistance [19]. Srinivasan et al. demon-
strated that 35 mg/kg STZ had no effect on insulin con-
centrations in chow fed rats, whereas high-fat feeding in
isolation increased insulin, with the combination of
high-fat and STZ bringing insulin concentrations back
to control levels [19]. Using a glucose tolerance test, they
demonstrated systemic insulin resistance with high-fat
diet alone [19]. Thus, it could be that our model using
30 mg/kg STZ mimics a later stage in type 2 diabetes-
insulin resistance disease progression, when β-cell func-
tion starts to become compromised and no longer
matches the increased demand for insulin.
In conclusion, a combination of high-fat feeding with
a low dose of STZ provides a model of type 2 diabetes
that mimics the metabolic phenotype present in patients.
This model also has the added advantages of being rela-
tively inexpensive, easy to induce and can be modified
for different severities of diabetes, according to require-
ment of the study. For future studies we would use a
dose of 25 mg/kg STZ in combination with high-fat
feeding, as this induced adiposity, hypercholesterolemia,
mild hyperglycaemia without compromising insulin se-
cretion, and exhibited cardiac metabolic changes that
mirrored the well characterised shift from glucose to
fatty acid metabolism in type 2 diabetes.
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